Biopharma & Life Sciences
Tyra Biosciences Executive Compensation (FY25)
TYRA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Todd Harris |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Tyra Biosciences brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (DEF 14A): April 17, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
119 figures on this page, cited to the filing that reported them. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Todd Harris: $7,570,066 → $5,566,997 (26.5% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Tyra Biosciences' chief executive and what were they paid?
Todd Harris was paid $5,566,997 in total compensation as President, Chief Executive Officer and Director for fiscal 2025. Harris' total was 26.5% lower than the $7,570,066 reported for fiscal 2024.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Todd Harris Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Hiroomi Tada Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Todd Harris Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Alan Fuhrman Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Hiroomi Tada Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Daniel Bensen Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Todd Harris Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Douglas Warner Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Daniel Bensen Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Todd Harris President, Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Bhavesh Ashar Chief Operating Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Douglas Warner Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Bhavesh Ashar | OPTION | — | — | — | — | — | — | ◇ |
| Douglas Warner | OPTION | — | — | — | — | — | — | ◇ |
| Todd Harris | OPTION | — | — | — | — | — | — | ◇ |
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Todd Harris | Option | ◇ | — | ◇ | 8/6/2035 |
| Option | ◇ | — | ◇ | 8/13/2034 | |
| Option | ◇ | — | ◇ | 7/27/2033 | |
| Option | ◇ | — | ◇ | 9/5/2032 | |
| Bhavesh Ashar | Option | ◇ | — | ◇ | 11/30/2035 |
| Douglas Warner | Option | ◇ | — | ◇ | 8/6/2035 |
| Option | ◇ | — | ◇ | 9/8/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Bhavesh Ashar
Chief Operating Officer · Terms as announced by the company
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-solicit period | ◇ |
Douglas Warner
Chief Medical Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Todd Harris
President, Chief Executive Officer and Director · Employment agreement
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Adele M. Gulfo | ◇ | — | ◇ | — | — | ◇ | ◇ |
Robert More Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Rehan Verjee | ◇ | — | ◇ | — | — | — | ◇ |
Jake Simson, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Susan Moran, M.D., M.S.C.E | ◇ | — | ◇ | — | — | — | ◇ |
Gilla Kaplan, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
S. Michael Rothenberg, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Nina Kjellson | ◇ | — | — | — | — | — | ◇ |
Todd Harris, Ph.D, Melissa McCracken, Ph.D and Habib J. Dable served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Todd Harris (President, Chief Executive Officer and Director), FY2025 total compensation $5,566,997 (base salary $658,000) [exec_comp, SEC accession 0001193125-26-160360, filed 2026-04-17]What this page does not include
Everything above is a fact Tyra Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
119 figures on this page, cited to the filing that reported them.
119 cited to the filing
Documents cited
- 0001193125-26-1603602025 Summary Compensation Table · CLASSDIRECTORS& · EXECUTIVE AND DIRECTOR COMPENSATION · Outstanding Equity Awards at 2025 Fiscal Year-End · and 1 more section
- 0001193125-25-085709
- 0001193125-24-100755
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Tyra Biosciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/TYRA (accessed 2026).
Short form: data: Velarion
The Tyra Biosciences brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Tyra Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}